Datapoint: FDA Approves Host of Vyvanse Generics

As the nationwide Adderall shortage continues, the FDA last week approved the first generic versions of Takeda’s blockbuster ADHD drug Vyvanse (lisdexamfetamine dimesylate). Manufacturers of the newly approved generics include Actavis, Mylan, Sun Pharmaceutical and Teva. For the treatment of ADHD, Vyvanse holds covered or better status for 88% of all insured lives under the pharmacy benefit. About 43% of lives have preferred access to Vyvanse without utilization management restrictions.

SOURCE: MMIT Analytics, as of 8/31/23

0

0

0 Comments

0

0

• Datapoint